Hepatocellular carcinoma (HCC) remains a major global health burden, and therapeutic resistance continues to limit the benefit from systemic treatment. Despite advances in systemic therapies, including immune checkpoint inhibitor-based combinations, antiangiogenic agents, and multitargeted tyrosine kinase inhibitors fo...
K. Li, F. Sun, S. Chan et al.· International Journal of Mol...· 0 citations
This case report illustrates the use of amivantamab in combination with pemetrexed-based chemotherapy for the treatment of a 60-year-old man with refractory metastatic upper tract urothelial carcinoma (UTUC) with epidermal growth factor receptor (EGFR) exon 20 insertion (D770_N771insGF) and methylthioadenosine phosphor...
K. Li, R. Leung, T. Yau et al.· Frontiers in Oncology· 0 citations
BACKGROUND & AIMS
First-line nivolumab demonstrated a higher objective response rate (ORR) and favorable safety profile vs. sorafenib in advanced HCC in the phase 3 CheckMate 459 trial; however, no significant improvement in overall survival (OS) was observed. Here, we report exploratory biomarker analyses from CheckMa...
J. Neely, Jin Yao, M. Kudo et al.· JHEP Reports· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.